UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

9 Year Follow-up After Initial Treatment with FC and FCR Regimens In Chronoc Lymphocytic Leukemia - Impact of pretreatment CIRS

Blood, 2011-11, Vol.118 (21), p.4616-4616

2011

Volltextzugriff (PDF)

Assessment of protective properties of glasses with the application of golmium oxide against Gamma radiation

AIP Conference Proceedings, 2022, Vol.2466 (1)

2022

Volltextzugriff (PDF)

Assessment of radiation-protective properties of Y2O3-MnO2-Al2O3-SiO2-CaO using Phy-X software and Geant4 simulation code

AIP Conference Proceedings, 2022, Vol.2466 (1)

2022

Volltextzugriff (PDF)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

Blood advances, 2023-06, Vol.7 (12), p.2794-2806

2023

Volltextzugriff (PDF)

The cost-effectiveness of treatment of relapsed/refractory chronic lymphocytic leukemia with a combination of venetoclax and rituximab

Sovremennaia onkologiia : zhurnal kafedry onkologii RMAPO dlia nepreryvnogo poslediplomnogo obrazovaniia, 2019-06, Vol.21 (2), p.29-32

2019

Volltextzugriff (PDF)

Effect of IGHV Gene Mutation Status and BCR Structure Stereotypy on Effectiveness of BR Regimen in First-Line Therapy of Chronic Lymphocytic Leukemia

Kliničeskaâ onkogematologiâ, 2017, Vol.10 (2), p.141-149

2017

Volltextzugriff (PDF)

Efficacy Of Different Therapeutic Approaches In Blastic Phase Of Chronic Myeloid Leukemia: Single Centre Experience

Blood, 2013-11, Vol.122 (21), p.5173-5173

2013

Volltextzugriff (PDF)

Efficacy of Ibrutinib in the Treatment of First Early Relapses of CLL

Clinical lymphoma, myeloma and leukemia, 2018-09, Vol.18, p.S216-S216

2018

Volltextzugriff (PDF)

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

Haematologica (Roma), 2022-09, Vol.107 (9), p.2108-2120

2022

Volltextzugriff (PDF)

Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia

BLOOD, 2018, Vol.132 (Supplement 1), p.5569-5569

2018

Volltextzugriff (PDF)

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

Blood, 2018-11, Vol.132 (Supplement 1), p.691-691

2018

Volltextzugriff (PDF)

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

The lancet oncology, 2019-01, Vol.20 (1), p.43-56

2019

Volltextzugriff (PDF)

Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia

Annals of hematology, 2018-11, Vol.97 (11), p.2153-2161

2018

Volltextzugriff (PDF)

Impact of MRD Eradication on Survival Outcomes in CLL Patients with Different IGHV Mutation Status

Clinical lymphoma, myeloma and leukemia, 2019-09, Vol.19, p.S273-S273

2019

Volltextzugriff (PDF)

Prospective Evaluation of Safety and Efficacy of BR Regimen in Previously Untreated CLL Patients

Clinical lymphoma, myeloma and leukemia, 2016-09, Vol.16, p.S46-S47

2016

Volltextzugriff (PDF)

Role of Patient's Age and Comorbidities in Therapy of Chronic Lymphocytic Leukemia

Kliničeskaâ onkogematologiâ, 2016, Vol.9 (2), p.162-175

2016

Volltextzugriff (PDF)

1 – 17 von 17

Suche als RSS-Feed

Aktive Filter

ThemaMiddle Aged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(17)
Mit Volltextzugriff
(11)

Publikationsform

Artikel
(14)
Tagungsberichte
(3)

Sprache

Englisch
(17)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

9 Year Follow-up After Initial Treatment with FC and FCR Regimens In Chronoc Lymphocytic Leukemia - Impact of pretreatment CIRS

Assessment of protective properties of glasses with the application of golmium oxide against Gamma radiation

Assessment of radiation-protective properties of Y2O3-MnO2-Al2O3-SiO2-CaO using Phy-X software and Geant4 simulation code

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

The cost-effectiveness of treatment of relapsed/refractory chronic lymphocytic leukemia with a combination of venetoclax and rituximab

Effect of IGHV Gene Mutation Status and BCR Structure Stereotypy on Effectiveness of BR Regimen in First-Line Therapy of Chronic Lymphocytic Leukemia

Efficacy Of Different Therapeutic Approaches In Blastic Phase Of Chronic Myeloid Leukemia: Single Centre Experience

Efficacy of Ibrutinib in the Treatment of First Early Relapses of CLL

First Line BR in Chronic Lymphocytic Leukemia Patients: Interim Results of Russian Norma Trial

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia

Impact of MRD Eradication on Survival Outcomes in CLL Patients with Different IGHV Mutation Status

Prospective Evaluation of Safety and Efficacy of BR Regimen in Previously Untreated CLL Patients

Role of Patient's Age and Comorbidities in Therapy of Chronic Lymphocytic Leukemia

Aktive Filter

Suchergebnisse filtern